Teva Pharmaceutical Industries Ltd (ADR) (TEVA)

Copy cat drugs have their cost behind them and can be produced pretty cheap and sold on the world market.

jbk - 61

generics, generics

Vacuuming up drugs as they become generic. Growing fast. Has a platoon of lawyers fighting (and winning) approval to get patented meds turn to generic sooner.

I have never been able to make any money in health care stocks. Bio-tech, generic or name brand pharmaceuticals, medical appliances, diagnostic or surgical support, 64 slice diagnostic scans, heart valves, doctor or patient education. For me, this is one elusive beast.

I've tried Harry Potter spells, I've talked to the trees and I've listened to the muse but this box remains locked. Nevertheless, undaunted and enthused by federal money targeted for this arena, I struggle on tip toe to catch but a few stray dollars.

Will I make it? Will TEVA's generics and Cardinal Health's packaging and distribution systems light my way? Stay tuned. Fate will be revealed right here in my CAPS portfolio. Check back often to see me crash and burn once again or succeed in spite of myself.

Just looking for a break out through the 25 & 50 MA. Short term trade.

It apparently has reached its peak for now. It is churning

Drugs coming off patent will make TEVA profitable. Their lean business model and cash flow is a plus.

solid pick

Teva will be a dividend monster of the future. Teva has increased its dividend each year by 34% average over the last ten years. Aging of developed nations' population will drive demand for pharmaceuticals in general for the remainder of our lives (anyone reading this). Generics, in particular, will benefit from the current effort to rein in escalating health costs. Teva, the largest generic-maker in the world, is right in the sweet spot for top line growth. At a forward PE of less than 12, Teva is an incredible bargain for a company that should double sales every 4-5 years. Current market angst over loss of Copaxone patent and worry about indigestion from Barr acquisition are holding the lid on this stock; short-term static, in my opinion. Buy this stock now and hold forever.

TEVA Pharmaceuticals is a large, established quality, generic drug manufacturer. More and more patients are moving to generic drugs to combat the high cost of the NAME brand drug. A huge market will be available to TEVA as Pfizer's LipitorR, for example comes off patent. Other drugs patents expire each year. TEVA is quick to move to the most attractive compounds.

TEVA is a Long-term buy - even in an uncertain market and turmoil in Healthcare.

Kahuna, CFA

Generics is the future.

Keeping drugs costs down means encouraging generic usage, copaxone is a very useful MS treatment, and the company is ruthlessly efficient.

Diversified, offering generics, patented, and raw chemicals. Bet against the dollar.

genaric will win out and this is a strong contender.i like it enought to buy it ,even though i feel a financial set back is ready this friday 8/26/2009 or next week.

http://seekingalpha.com/article/157183-teva-pharmaceutical-predictable-growth-good-value?source=feed

More people getting older-faster, more drugs = more money

Extremely defensive and while the bad news on Barr will hurt the mkt will overeact and then come running back to Teva to find a place to hide from the coming correction.

Outstanding company in the growing field of generics.